Moringa seed extract containing 1-O-(4-hydroxy-methylphenyl)-α-l-rhamno-pyranoside (GR) has been reported to ameliorate CCl4 induced hyperlipidemia in the liver. However, it is unclear whether GR has any therapeutic effect on NAFLD. This study aimed to determine the hypolipidemic and concomitant hepatoprotective potential of GR. The structure and purity of GR were assessed and characterized using high performance liquid chromatography-mass spectrometry (UPLC-MS/MS). The NAFLD model was established based on the L02 cells in vitro. After GR intervention, intracellular fat deposition and reactive oxygen content were significantly reduced, GR could up-regulation of AMPK and PPARα and the down-regulation of mTOR and SREBP-1, which play a key role in liver lipid homeostasis. In vivo experiments revealed that GR intervention significantly decreased serum fat content, inhibited liver injury, and increased antioxidant mechanism in mice fed with high fat diet. Hence, GR demonstrated promising hypolipidemic and hepatoprotective activities, serving as a potential candidate for NAFLD therapy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.foodchem.2022.132087 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Network pharmacology uncovers that secoisolariciresinol diglucoside ameliorate premature ovarian insufficiency via PI3K/Akt pathway.
Sci Rep
January 2025
School of Basic Medical Sciences, Jiangxi Medical College, Nanchang University, No.461 Bayi Road, Donghu District, Nanchang, 330006, Jiangxi Province, People's Republic of China.
As one of the essential lignan derivative found in traditional Chinese medicinal herbs, secoisolariciresinol diglucoside (SDG) was proved to promote women's health through its phytoestrogenic properties. Increasingly studies indicated that this compound could be a potential drug capable of preventing estrogen-related diseases. Here, we aimed to investigate whether SDG can counteract cyclophosphamide (CTX) induced premature ovarian insufficiency (POI) and further explore its specific molecular mechanism.
View Article and Find Full Text PDFGlycyrrhizic acid reduces neutrophil extracellular trap formation to ameliorate colitis-associated colorectal cancer by inhibiting peptidyl arginine deiminase 4.
J Ethnopharmacol
January 2025
State Key Laboratory of Traditional Chinese Medicine Syndrome, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China; Chinese Medicine Guangdong Laboratory, Guangdong Hengqin, 519000, China. Electronic address:
Ethnopharmacological Relevance: In traditional Chinese medicine, the radices of Glycyrrhiza uralensis Fisch, known as liquorice, have been used for relieving cough, alleviating pain and harmonizing the actions of all medicinals in a formula. Glycyrrhizic acid (GA), a natural compound derived from licorice, exhibits notable anti-inflammatory properties.
Aim: Neutrophil extracellular trap (NET) generated by peptidylarginine deiminase 4 (PAD4) has been implicated in the progression of colitis to colitis-associated colorectal cancer (CAC).
Background: Senile dementia (SD) is a deteriorative organic brain disorder and it comprises Alzheimer's disease (AD) as a major variant. SD is shown impairment of mental capacities whereas AD is degeneration of neurons. According to World Health Organization (WHO) report; more than 55 million peoples have dementia and it is raising 10 million new cases every year.
View Article and Find Full Text PDFBackground: Alzheimer's disease (AD) is a neurodegenerative disorder without a cure. Targeting this multifactorial disease by repurposing FDA approved drugs serves as a faster mode of treatment due to its pre-established human safety. We tested terazosin (TZ), an a-1 adrenergic receptor (AR) antagonist and phosphoglycerate kinase-1 (PGK1) activator as having potential to treat AD.
View Article and Find Full Text PDFBackground: Previously, we demonstrated therapeutic benefits following intraperitoneal delivery of the TGR5 agonist HY209 in 5xFAD, a transgenic mouse model of Alzheimer's Disease (AD). Given the desirability of a more acceptable administration route for prolonged AD treatment, we assessed the efficacy of HY209 via oral delivery. This study aims to elucidate the therapeutic potential of NuCerin, an oral formulation of HY209, in the aforementioned AD model, while simultaneously identifying potential blood biomarkers indicative of NuCerin's therapeutic action.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!